Overall, these data support the hypothesis that combined inhibition of MMP-9 and PDL1 drives a Th1-type anti-tumor immune response by decreasing physical ECM barriers and increasing protein levels of Th1-type cytokines, trafficking of effector-memory T cells into tumors, and boosting intratumoral T-cell diversity. This evidence concerns the gene MMP9 and neoplasm.